In our last two episodes we discussed the impact of U.S. policy shifts on global FDA-regulated products supply chain and shared industry perspectives on global supply chain disruptions. On today’s episode, we unpack the sweeping tax reforms introduced by the One Big Beautiful Bill Act signed into law on July 4, 2025. With major changes to R&D expensing, international tax regimes, and incentives for domestic manufacturing, the bill is poised to reshape the global pharmaceutical supply chain. We explore how these provisions affect multinational pharma companies’ supply chain strategies.
